Impact of BRAF-V600E mutation on the tumour microenvironment and associated genomic alterations ...

Dr Mohamed Salem talks to ecancer about a talk he presented at ESMO GI 2022 on the impact of BRAF-V600E mutation on immunologic characteristics of the tumour microenvironment and associated genomic alterations in microsatellite instability-high (MSI-H) or mismatch-repair-deficient colorectal cancer. He begins by explaining the rationale behind the study before detailing the design and patient criteria. Dr Salem believes that the results show that, among those tumours with MSI-H status, there is no significant difference in the tumour microenvironment with BRAF-V600E mutation or wild-type status, suggesting that both should be equally responsive. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php

Optimizing Testing and Treatment of Patients with BRAFV600E-mutant mCRC in Community Practice
▶︎

Optimizing Testing and Treatment of Patients with BRAFV600E-mutant mCRC in Community Practice

BRAF-Mutated mCRC: From Diagnosis to Treatment
▶︎

BRAF-Mutated mCRC: From Diagnosis to Treatment

BRAF V600E Status Effect on Lymph Node-Metastasis-associated Mortality in PTC with Dr. Linwah Yip
▶︎

BRAF V600E Status Effect on Lymph Node-Metastasis-associated Mortality in PTC with Dr. Linwah Yip

How to Approach the Patient With BRAF Mutant Tumor
▶︎

How to Approach the Patient With BRAF Mutant Tumor

Incorporation of BRAF–Targeted Therapy into Neuro Oncology Clinical Practice - Karisa Schreck, M.D.
▶︎

Incorporation of BRAF–Targeted Therapy into Neuro Oncology Clinical Practice - Karisa Schreck, M.D.

Genetics and Targeting of Advanced Thyroid Cancer - M. Ringel
▶︎

Genetics and Targeting of Advanced Thyroid Cancer - M. Ringel

KRAS mutation
▶︎

KRAS mutation

The World's Most Important Machine
▶︎

The World's Most Important Machine

Can We Increase the Immunogenicity in MSS CRC?
▶︎

Can We Increase the Immunogenicity in MSS CRC?

BREAKWATER Trial Signals New First-Line Option for BRAF V600E CRC
▶︎

BREAKWATER Trial Signals New First-Line Option for BRAF V600E CRC

BRAF Mutations in NSCLC - 2022 Program: Targeted Therapies Forum
▶︎

BRAF Mutations in NSCLC - 2022 Program: Targeted Therapies Forum

💥ЗЕЛЕНСЬКОГО ПЕРЕГРАЛИ! Восени трагічний ФІНАЛ ВІЙНИ. Крах України БЛИЗЬКО? / ЦИБУЛЬКО, ЧОРНОВІЛ
▶︎

💥ЗЕЛЕНСЬКОГО ПЕРЕГРАЛИ! Восени трагічний ФІНАЛ ВІЙНИ. Крах України БЛИЗЬКО? / ЦИБУЛЬКО, ЧОРНОВІЛ

Thyroid Cancer Treatment Varies by Physician & Environment with Dr. Toro-Tobon
▶︎

Thyroid Cancer Treatment Varies by Physician & Environment with Dr. Toro-Tobon

BREAKWATER Breakthrough: A New Era for BRAF V600E CRC
▶︎

BREAKWATER Breakthrough: A New Era for BRAF V600E CRC

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
▶︎

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

Changing Treatment Paradigm for BRAF-Mutant NSCLC
▶︎

Changing Treatment Paradigm for BRAF-Mutant NSCLC

I NEVER thought My SYMPTOMS would be STAGE 4 Cancer - Mags | Lymphoma (PMBL) | The Patient Story
▶︎

I NEVER thought My SYMPTOMS would be STAGE 4 Cancer - Mags | Lymphoma (PMBL) | The Patient Story

Excel for Finance and Accounting Full Course Tutorial (3+ Hours)
▶︎

Excel for Finance and Accounting Full Course Tutorial (3+ Hours)

Molecular Markers for Thyroid Cancer - Masha Livhits, MD & Michael Yeh, MD | UCLAMDChat
▶︎

Molecular Markers for Thyroid Cancer - Masha Livhits, MD & Michael Yeh, MD | UCLAMDChat

Encorafenib + cetuximab (EC) BREAKWATER Study in BRAF V600E-Mutant Metastatic Colorectal Cancer
▶︎

Encorafenib + cetuximab (EC) BREAKWATER Study in BRAF V600E-Mutant Metastatic Colorectal Cancer